

## **CLINICAL GUIDELINE**

## **Acute Cardiac Chest Pain**

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

Version Number:	2
Does this version include changes to clinical advice:	Yes
Date Approved:	17 <sup>th</sup> January 2024
Date of Next Review:	30 <sup>th</sup> September 2026
Lead Author:	Faheem Ahmad
Approval Group:	Medicines Utilisation Subcommittee of ADTC

## **Important Note:**


The Intranet version of this document is the only version that is maintained.

Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

## **Acute Cardiac Chest Pain Guidelines**



This guideline covers patients who are suspected to have acute cardiac chest pain. As of 6th November 2023, in patients with **new ACS**, clopidogrel is the first choice (not ticagrelor). Patients **post-PCI** will be commenced on prasugrel and transferred back to NHS GGC.



Approved by: Heart MCN (September 2023) Revision Date: September 2026